PROgastrine COlon DEpistage

Not Applicable

Terminated

• Conditions: Healthy Person; Colon Cancer Screening
• Interventions: Diagnostic Test: progastrin

• Registration Number: NCT03775473
• Lead Sponsor: ECS-Progastrin SA

Brief Summary

Dosage of progastrin in asymptomatic person participating in colon cancer screening

Detailed Description

For anyone who will participate in colon screening at the Princess Grace Hospital of Monaco and who has signed the informed consent document. A blood test will be performed in addition to the screening test to assess the rate of progastrin.

Study Timeline

• Study First Submitted: 2018-12-07
• Study First Submitted QC: 2018-12-11
• Study First Posted: 2018-12-14
• Study Start: 2019-02-07
• Primary Completion: 2021-02-05
• Study Completion: 2021-12-17
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-12
• Last Update Posted: 2022-01-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 260

Inclusion Criteria

• participant in colon cancer screening
• signing informed consent

Exclusion Criteria

• any major medical, psychiatric or addictive illness that would affect the informed consent process
• The consent of a representative is not allowed in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
progastrin	progastrin	anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document

Primary Outcome Measures

Name	Time	Method
progastrin rate	from 15 days to 2 months (until results are obtained)	measuring the rate of progastrin in the blood

Trial Locations

Locations (1)

Centre Hospitalier Princesse Grace, Monaco; 🇫🇷 Montpellier, MC, France